Science and Research

Exacerbations of COPD

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed. More severe exacerbations should be treated with beta-agonists and anticholinergics as well as systemic corticosteroids. Antibiotic therapy should only be given to patients with presumed bacterial infection. Noninvasive ventilation is indicated in patients with respiratory failure. Smoking cessation is key to prevent further COPD exacerbations. Other aspects include choice of pharmacotherapy, including bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, long-term antibiotics and mucolytics. Better education and self-management as well as increased physical activity are important. Influenza and pneumococcal vaccination is recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of COPD exacerbations, while most interventional bronchoscopic therapies increase exacerbation risk within the first months after the procedure.

  • Viniol, C.
  • Vogelmeier, C. F.

Keywords

  • Anti-Bacterial Agents/adverse effects/*therapeutic use
  • Bronchodilator Agents/adverse effects/*therapeutic use
  • Disease Progression
  • Exercise
  • Health Knowledge, Attitudes, Practice
  • Healthy Diet
  • Humans
  • Lung/*drug effects/physiopathology
  • Noninvasive Ventilation/adverse effects/*methods
  • Patient Education as Topic
  • Pulmonary Disease, Chronic
  • Obstructive/diagnosis/epidemiology/physiopathology/*therapy
  • Risk Factors
  • *Risk Reduction Behavior
  • Self Care/adverse effects/*methods
  • Smoking Cessation
  • Treatment Outcome
  • Mundipharma, outside the submitted work. C.F. Vogelmeier has received personal
  • fees from Almirall, Cipla, Berlin Chemie/Menarini, CSL Behring and Teva. He has
  • received grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi,
  • GlaxoSmithKline, Grifols, Mundipharma, Novartis and Takeda. He has received
  • grants from the German Federal Ministry of Education and Research (BMBF)
  • Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and
  • Pfizer, outside the submitted work.
Publication details
DOI: 10.1183/16000617.0103-2017
Journal: European respiratory review : an official journal of the European Respiratory Society
Number: 147
Work Type: Review
Location: UGMLC
Disease Area: COPD
Partner / Member: UMR
Access-Number: 29540496
See publication on PubMed

DZL Engagements

chevron-down